Genitourinary Medical Oncology Clinic

Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer

The Decisional Conflict Scale measures personal perceptions of : a) uncertainty in choosing options; b) modifiable factors contributing to uncertainty such as feeling uninformed, unclear about personal values and unsupported in de...

Recruiting

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combina...

Objective response rate, defined as the proportion of participants with a CR or PR on two consecutive occasions >=4 weeks apart during Stage 1, as determined by the investigator according to RECIST v1.1.

Recruiting

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostat...

A minimum of 3 patients will be treated at each dose level. If < 33%of patients (i.e. 0 of 3 patients, or 1 of 6 patients) within a cohort have a dose-limiting toxicity (DLT in Cycle 1, then enrollment of the next cohort may comme...

Recruiting

A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

Descriptive statistics will be used to summarize results.

Recruiting

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation ...

Adverse events, serious adverse events, and dose limiting toxicities

Recruiting

Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prost...

The composite response rate is determined by a combination of a decline from baseline in serum PSA of >= 50%, confirmed by repeat measurement ≥ 4 weeks later (PSA50) AND/OR a complete response (CR) or partial response (PR) as dete...

Recruiting

A Study of Tarlatamab (AMG 757) in Participants With Neuroendocrine Prostate Cancer

Recruiting

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant ...

Defined as either objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (complete response (CR), partial response (PR)) or confirmed >= 50% decline from serum prostate-specific antigen (PSA) at ...

Recruiting

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Ca...

ORR defined as the composite proportion of participants with a Prostate Specific Antigen (PSA) and/or radiographic complete response (CR) and partial response (PR) determined by the investigator according to the Prostate Cancer Wo...

Recruiting

68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

The mean SUVmax and standard deviation across the primary tumor and the 5 largest lesions in each of three metastatic sites (nodal, visceral and osseous; for a maximum of 16 lesions per patient) will be descriptively reported.

Recruiting